BioSpace News Archive

DUBAI, United Arab Emirates, The global cancer tissue diagnostics industry is hugely driven by sheer number of biomarkers used for early cancer detection from blood or plasma, while prevalence of lung, breast and prostate cancers has been another constant driving factor to the demand growth.

The global home diagnostics market is witnessing a growth and shall continue to expand at a high pace on account of the rising disposable income of people across nations, which enable them to afford products that enable self care.

With the advent of new technology, the potential that next generation sequencing application holds in genetic counseling, disease management and treatment, and risk assessment is remarkable.

Rhizen Pharmaceuticals AG, a Switzerland-based privately held, clinical-stage biopharmaceutical company announced that it is presenting promising interim data from an ongoing Ph2 trial of Tenalisib in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany from May 3-5, 2022.

Sanofi launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations.

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and financial results for the first quarter of 2022.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced a revenue interest financing of up to $260 million in non-dilutive capital.

Allena Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with an investor for the issuance and sale of an aggregate of 1,436.0688 shares of its Series D Convertible Preferred Stock, and 1,436.0688 shares of its Series E Convertible Preferred Stock in a registered direct offering for an aggregate gross proceeds of approximately $2.8 million, before deducting placement agent fees and other offering expenses.

Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tools for the job, acquired NanoView Biosciences today.

Graphite Bio, Inc. announced that members of the management team will participate in fireside chats at the following investor conferences.